Who are lipid-lowering drug(Statin)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, statin, amlodipine, Niacin Extended Release/Lovastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipid-lowering-drug-statin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

lipid-lowering drug(Statin) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lipid-lowering drug(Statin) (lipid-lowering drug(Statin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA reductase inhibitor (Statin). Area: Cardiovascular.

marketed HMG-CoA reductase inhibitor (Statin) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

lipid-lowering drug(Statin) (lipid-lowering drug(Statin)) — First Affiliated Hospital of Wenzhou Medical University. Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lipid-lowering drug(Statin) TARGET	lipid-lowering drug(Statin)	First Affiliated Hospital of Wenzhou Medical University	marketed	HMG-CoA reductase inhibitor (Statin)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
statin, amlodipine	statin, amlodipine	Gachon University Gil Medical Center	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor + dihydropyridine calcium channel blocker	HMG-CoA reductase; L-type calcium channels
Niacin Extended Release/Lovastatin	Niacin Extended Release/Lovastatin	In His Image	marketed	Statin/Niacin combination; Lipid-modifying agent	HMG-CoA reductase (lovastatin); GPR109A/PUMA-G receptor (niacin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (HMG-CoA reductase inhibitor (Statin) class)

First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lipid-lowering drug(Statin) — Competitive Intelligence Brief. https://druglandscape.com/ci/lipid-lowering-drug-statin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab